iRhythm Technologies, Inc.
HealthcareNASDAQ:IRTC · NASDAQ Global Select
+$0.98 today
Vol 0.28M · Avg 0.53M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-29.2%
avg -43.7%
ROIC
-4.2%
avg -27.5%
ROA
-4.4%
avg -23.5%
Analysis
ROIC is currently the strongest return metric at -4.2% versus its period average of -27.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Quentin S. Blackford | President, Chief Executive Officer & Director | $2.08M | — | 47 | $204,333.00 | 0.62% |
Chad Patterson | Chief Commercial and Product Officer | $1.28M | — | 44 | $58,341.00 | 0.18% |
Minang Turakhia | Chief Medical & Scientific Officer and Executive Vice President of Advanced Technologies | $1.03M | — | 52 | $55,043.00 | 0.17% |
Patrick Michael Murphy | Chief Business & Legal Officer | $987,343.00 | — | 47 | $65,532.00 | 0.20% |
Daniel G. Wilson | Chief Financial Officer & Principal Financial Officer | $970,199.00 | — | 44 | $14,211.00 | 0.04% |
Marc Rosenbaum | Senior Vice President of Finance & Chief Accounting Officer | — | — | 53 | $17,123.00 | 0.05% |
Lisa Pecora | Senior Vice President of Finance & Investor Relations | — | — | — | — | — |
Sean Clinton Freeman | Executive Vice President of Strategy & Corporate Development | — | — | 50 | $14,559.00 | 0.04% |
Brian Lawrence | Executive Vice President & Chief Technology Officer | — | — | 56 | $7,171.00 | 0.02% |
Mervin Smith | Executive Vice President of Business Operations | — | — | 51 | $23,027.00 | 0.07% |
Julie Rodda | Executive VP, Chief People & Capability Officer | — | — | 45 | $20,313.00 | 0.06% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$56,891.52
Sells
72
$30.20M
Net Sentiment
$30.15M
Net selling
Most Active
TALWALKAR ABHIJIT Y
18 transactions
1–10 of 73
Analysis
Insiders reported 1 buys worth $56,891.52 and 72 sells worth $30.20M over the last 12 months. That adds up to net selling of $30.15M. TALWALKAR ABHIJIT Y was the most active insider with 18 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +65.8% | +24.4% (13yr)4 analysts |
| Net Income | N/A | N/A | N/A | N/A4 analysts |
| EBIT | N/A | N/A | N/A | N/A4 analysts |
Analysis
Recent growth has been strongest in Revenue at +65.8% over three years. Forward estimates point to Revenue at +24.4% (13yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
BrightSpring Health Services, Inc. Common Stock
NASDAQ:BTSG
$12.26B
Arrowhead Pharmaceuticals, Inc.
NASDAQ:ARWR
$10.50B
Bruker Corporation
NASDAQ:BRKR
$8.26B
Glaukos Corporation
NYSE:GKOS
$7.45B
Vaxcyte, Inc.
NASDAQ:PCVX
$6.85B
Teleflex Incorporated
NYSE:TFX
$5.78B
Chemed Corporation
NYSE:CHE
$5.57B
Bausch + Lomb Corporation
NYSE:BLCO
$5.38B
CRISPR Therapeutics AG
NASDAQ:CRSP
$4.80B
RadNet, Inc.
NASDAQ:RDNT
$4.46B
Who manages IRTC?
iRhythm Technologies, Inc. (IRTC) lists 11 active executives. The top listed executive is Chad Patterson, Chief Commercial and Product Officer.
Are IRTC insiders buying or selling?
Recent insider activity shows net selling of $44.54M.
Explore More
Continue the stock analysis
Jump to another research area for this company.